Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Cachexia Stories

2012-10-15 03:23:48

LUGANO, Switzerland and MELBOURNE, Australia, Oct. 15, 2012 /PRNewswire/ -- Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia. This condition is a serious multifactorial disorder which involves muscle wasting and metabolic impairment and commonly affects patients with advanced cancer. STA has reached agreement with Swiss pharmaceutical company...

2012-10-05 02:23:44

NEW YORK, Oct. 5, 2012 /PRNewswire/ -- Ohr Pharmaceutical (OTCBB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced today that Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical, will be presenting at the 11(th) annual BIO Investor Forum taking place at The Palace Hotel in San Francisco on October 9-10, 2012. Dr. Taraporewala's presentation will include an overview of Ohr's clinical wet-AMD eye drop...

2012-10-03 10:24:26

AUSTIN, Texas, Oct. 3, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia drug Xilonix. The Company's groundbreaking therapeutic antibody was shown in a previous clinical study at MD Anderson Cancer Center in Texas to stop or reverse cachexia in about a third of all advanced cancer patients treated. Anti-tumor and anti-cachexia effects were seen in many different types of...

2012-09-25 06:27:11

WICHITA, Kan., Sept. 25, 2012 /PRNewswire-USNewswire/ -- Inflammatory responses play roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis. The 'inflammation- cancer' connection is not restricted to increased risk for a subset of tumors. An inflammatory component is present in the microenvironment of most neoplastic tissues. High inflammatory levels appear to indicate increased cancer risk and poorer prognosis....

2012-08-28 02:28:10

QUÉBEC CITY, Aug. 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia. The study is conducted under a Cooperative Research and Development Agreement (CRADA) between Aeterna Zentaris and the Michael E. DeBakey Veterans Affairs Medical Center which is funding the study. Cachexia,...

2012-03-08 06:30:00

Trial conducted through a Cooperative Research and Development Agreement QUÉBEC CITY, March 8, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Michael E. DeBakey Veterans Affairs Medical Center, in Houston, Texas, has initiated a Phase 2A trial assessing the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130 (macimorelin), in patients with cancer cachexia. The study is...

2011-12-07 06:00:00

LUGANO, Switzerland, Dec. 7, 2011 /PRNewswire/ -- Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics Inc., has enrolled the first patient in ROMANA-3, the Company's 12-week safety extension study. The ROMANA-3 safety extension study is recruiting patients who have successfully completed ROMANA 1 or ROMANA 2, the Company's two phase III studies running in parallel that are evaluating anamorelin HCI for the treatment of...

2011-11-28 06:30:00

QUÓ°BEC CITY, Nov. 28, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an...

2011-08-23 05:00:00

LUGANO, Switzerland, Aug. 23, 2011 /PRNewswire/ -- Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer (NSCLC). The anamorelin clinical program includes two pivotal Phase III studies to be run in parallel, named ROMANA-1 and ROMANA-2. Each is...

2010-12-27 07:02:00

MORRISTOWN, N.J., Dec. 27, 2010 /PRNewswire/ -- Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia. The randomized, open label, multi-center Phase 2 study will evaluate whether VT-122 in...